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Edited by Frances ShannonAbstract The members of the p38 mitogen-activated protein
kinase, especially speciﬁc inhibitors such as SB203580 sensitive
isoforms, have been shown to play important roles in immune
responses as well as in many biological events. In the course of
our study to understand how p38 can be responsible for numerous
biological phenomena, we have recently identiﬁed Exip, an
alternative splicing variant of p38a. Exip retains amino acids
responsible for the sensitivity to SB203580. Exip may also be
involved in the intracellular signal transduction pathway diﬀerent
from those of conventional p38s. Though Exip is less abundant, it
may play a critical role under certain circumstances. Here we
report that Exip, but not p38a, binds to Toll interacting protein
which is involved in interleukin-1 (IL-1) signaling pathway as a
component of the receptor proximal complex and impaired NF-
jB activity. Moreover, Exip binds to another component of the
complex, IL-1 associating kinase. Exogenous-expression of Exip
resulted in downregulation of NF-jB activities both in HeLa and
HEK293T cells. Together, these results demonstrate that Exip
can be a new component of NF-jB pathway, and contribute to a
comprehensive understanding of the signal transduction pathway
in the inﬂammatory responses.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.1. Introduction
Interleukin-1 (IL-1) signaling pathway plays a key role in
inﬂammatory responses [1]. Once pro-inﬂammatory cytokine
IL-1a or b binds to IL-1 receptor (IL-1R), IL-1R and IL-1R
associated protein (IL-1RAcP), an initial complex is formed
and MyD88 is recruited [2]. Simultaneously, IL-1 receptor
associating kinase (IRAK)–Toll-interacting protein (Tollip)
complex is recruited to the cytoplasmic domain of IL-1R
complex to initiate IL-1 signaling. Tollip was ﬁrst identiﬁed as
an adapter protein that binds to IL-1RAcP and IRAK, and
negatively regulates NF-jB activity [3].* Corresponding author. Fax: +81-48-462-4669.
E-mail address: sudo@riken.jp (T. Sudo).
Abbreviations: MAPK, mitogen-activated protein kinase; IL-1, inter-
leukin1; IRAK, IL-1 receptor associating kinase; Tollip, Toll-interact-
ing protein
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(MAPK) were identiﬁed as either an anti-inﬂammatory drug
(cytokine-suppressive anti-inﬂammatory drug) binding pro-
tein, a lipopolysaccharide activated protein kinase or a
stress-responsive protein kinase [4–6]. At least four members
of p38 family have been identiﬁed to date. Among them,
p38a and p38b have been shown to play important roles not
only in inﬂammatory responses but also in many biological
events including, apoptosis, diﬀerentiation, development and
so on [7–10]. In the middle of our eﬀort to understand how
p38 can be responsible for numerous biological phenomena,
we showed that p62, which has been shown to bind to
p56lck [11], atypical PKCs [12] and RIP [13], also binds and
regulates p38 [14]. The study somehow explained how var-
ious environmental stimuli exert diﬀerent responses in cell
type- and/or in the stimulation-dependent fashions by using
a limited number of signal transducers. Then, we identiﬁed a
new splice variant of p38a, Exip. Exip is predicted to en-
code a 307 amino acid protein with a unique 53 amino acid
C-terminus caused by the shift of the reading frame in
protein synthesis [15]. The expression of mRNA was barely
observed in cultured cells tested. Exip retained amino acids
responsible for the sensitivity to SB203580 but lost a com-
mon docking domain well conserved in major MAPK
families for their speciﬁc interactions with upstream kinases
or downstream substrates. Even though, Exip is not phos-
phorylated at conserved TGY motif [16] by p38 activating
treatments, such as an osmotic shock or co-expression with
a constitutive active form of MKK6 in HeLa cells, Exip can
induce apoptosis in HeLa cells [15]. In spite of maintaining
almost all the kinase catalytic domains except for conserved
subdomain XI of the protein kinase family [17], we could
not detect kinase activity of Exip with conventional methods
represented by auto-phosphorylation, in gel kinase assay
and so on. This suggests that Exip has unique properties as
a member of p38a and plays diﬀerent role(s). Although
major roles attributed to the speciﬁc inhibitor sensitive
functions of p38 might be carried out by p38a, Exip may
play a critical role under certain circumstances. This situa-
tion urged us to explore the roles of Exip in the entire p38
signal pathways.
Here we report that Exip, but not p38a, binds to Tollip, and
participates in NF-jB pathway as a negative regulator. Exip
also binds to IRAK as well as Tollip, indicating possible in-
volvement of Exip in the receptor proximal complex in IL-1
signaling.blished by Elsevier B.V. All rights reserved.
Fig. 1. Structures of Exip and Tollip. (A) A schematic protein comparison for human Exip and p38a. A hatched box represents an Exip speciﬁc
domain used in the screening. Solid box denotes the common docking domain conserved in MAPKs [21]. A catalytic center and a conserved
threonine residues necessary for speciﬁc inhibitor binding are indicated [22,23]. The TGY motif speciﬁc for p38 family is also indicated [16]. (B) The
protein structure of human Tollip. A hatched box represents the domain bound to Exip peptide in the screening. CUE domain is indicated [20].
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2.1. Plasmid constructions
The plasmid pAS2-1-ExipC, which encodes the Gal4DB (DNA
binding domain) fused to Exip fragment (Leu255–Leu307), was
constructed as follows. We designed two primers, 50-CAT-
GCCATGGAGCTGTCGACTTGCTGG-30, which corresponds to
the nucleotides from 763 to 777 of human Exip translation start site
and an artiﬁcial NcoI site to facilitate further cloning, and 50-
CGGATCCCTATAAGGAGGTCCCTGCTTTC-30, which corre-
sponds to the nucleotides from 924 to 902 and an artiﬁcial BamHI site.
We performed PCR ampliﬁcation using pcDNA3FlaghExip [15] as a
template. The PCR product was digested and inserted into the NcoI
and BamHI sites of pAS2-1 (CLONTECH). The DNA sequence was
conﬁrmed by the ABI system.
2.2. Yeast two-hybrid screening
pAS2-1-ExipC was used to screen a pretransformed Human Heart
MATCHMAKER cDNA Library (CLONTECH). Approximately
3 107 transformants were screened according to the manufacturer’s
protocol. We obtained 6 positive clones, one of which contained se-
quences derived from the Tollip mRNA. We cloned the full-length
coding region of Tollip (274 amino acids) by PCR ampliﬁcation of a
HL-60 cDNA. The DNA sequence was conﬁrmed by the ABI system.
2.3. Cell culture
HEK293T and HeLa cells (RIKEN Cell Bank, Tsukuba, Japan)
were cultured in Dulbecco’s modiﬁed Eagle’s medium (Sigma) sup-
plemented with 10% (v/v) fetal bovine serum (Invitrogen), 50 units/ml
penicillin, and 50 lg/ml streptomycin (Sigma) at 37 C with 5% CO2.
2.4. Co-immunoprecipitation assay
The transient transfection was performed by using Eﬀectene (Qia-
gen). Brieﬂy, 1 105 of HeLa or 2 106 of HEK293T cells were seeded
into a 60-mm tissue culture plate and the next day, indicated plasmids
were transfected according to the manufacturer’s instructions. These
cells were grown in DMEM supplemented with 10% FCS for 24 h. Co-
immunoprecipitation assays were conducted using monoclonal anti-
Flag antibody (M2, Sigma–Aldrich) or polyclonal anti-HA antibody
(Santa Cruz). Cells were harvested and lysed in a buﬀer containing 50
mM Tris–HCl (pH 7.5), 100 mM NaCl, 1% TritonX-100, 20 mM b-
glycerophosphate, 1 mM sodium orthovanadate, 1 mM PMSF, and 10
lg/ml leupeptin. Then, the samples were rotated for 1 h at 4 C fol-
lowed by 15 min centrifugation at 15 000 rpm at 4 C. These lysates
were precleared by the addition of protein A sepharose beads
(Amersham Pharmacia Biotech) followed by brief centrifugation.
Then, antibody prebound protein A beads were mixed with the lysates
containing 300 lg of total protein and rotated for 12 h at 4 C. After
three washes with the lysis buﬀer, proteins that bound the aﬃnity
beads were separated by 12% SDS–polyacrylamide gel electrophoresis
followed by Western blot analysis.
2.5. Antibodies
Western blot analysis was conducted using anti-FLAG M2 mono-
clonal antibody (Sigma–Aldrich), anti-HA tag monoclonal antibody(Santa Cruz), anti-IRAK antibody (Santa Cruz). Signals were visual-
ized as described [15].
2.6. Luciferase reporter assay
HeLa cells were plated at a density of 0.25 105 cells/well in 24-well
plates 1 day before transfection. Cells were transfected using Eﬀectene
with 0.025 lg of 3 · NF-kB-Luc and the increasing amounts of
pcDNA3-Flag-hExip, pcDNA3-3HA-Tollip with or without 0.025 lg
IRAK/pEF-BOScDNA. Total amounts of plasmid DNA were nor-
malized to 0.2 lg by addition of pcDNA3FN (pcDNA3 with Flag-tag).
After 24 h, cells were either left untreated or stimulated with 10 ng/ml
IL-1b for 6 h. Cells were lysed in a buﬀer containing 100 mM Tris–
acetic acid (pH 7.8), 10 mM magnesium-acetate, 1 mM EDTA, 0.1%
TritonX-100 and 1 mM DTT. 20 lg of total proteins was applied for
luciferase assay. The same experiments were carried out at least three
times and a representative result is shown.3. Results and discussion
3.1. Molecular cloning of Tollip as an Exip binding protein
For the ﬁrst step in studying the physiological function of
Exip, we carried out a yeast two-hybrid screening to identify
the protein that speciﬁcally binds to Exip. By using the C-
terminal peptide of Exip (residues 255–307, Fig. 1A and [15])
as a bait, about 3 107 transformants derived from HeLa
cDNA were screened and 6 positive clones were found to bind
to Exip in the yeast system. Further studies showed that one of
the positive clones had the cDNA encoding C-terminal half of
Tollip (residues 142–274, Fig. 1B). Tollip has been identiﬁed as
an adapter protein in the receptor proximal complex in IL-1
signaling and suggested to downregulate NF-jB activity in
response to IL-1 [3]. It has also been shown to impair NF-jB
and AP-1 activities in Toll Like Receptors (TLRs) signaling
pathways [18]. These results suggested that Tollip plays an
important role in an innate immune system. In addition to the
suggestive role in an innate immune system, recent study in-
dicated that Tollip may be involved in the intracellular traf-
ﬁcking system by binding to Tom1, ﬁrst identiﬁed as a target of
transcription factor v-myb, through N-terminus [19]. This
complex further binds to clathrin to function as a clathrin-
mediated endosomal protein sorting. Another study shows
that Tollip interacts with monoubiquitin through CUE do-
main (Fig. 1B, [20]). These observations correlate well to Ex-
ip’s feature of localizing exclusively in the cytoplasm [15].
Though we tested the possible involvement of ubiquitin-
dependent protein degradation system in the regulation of Exip
by introducing Lysine to Arginine substitutions in Exip speciﬁc
Fig. 2. Exip binds to Tollip. (A) Exip, but not p38a, binds to Tollip in
HeLa cells. Top panel shows the comparative expressions of Exip and
p38a. The second panel shows equal expression of Tollip. The third
panel shows comparative eﬃciencies of immunoprecipitation experi-
ments. Bottom panel shows that Tollip is speciﬁcally co-precipitated
with Exip. (B) Exip binds to Tollip irrespective to IL-1b stimulation.
Fig. 3. Exip as well as Tollip binds to IRAK. (A) Tollip binds to IRAK
in an immunoprecipitation assay in HEK293T cells. (B) Exip binds to
IRAK.
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NF-jB activity and protein stability (data not shown).
3.2. Exip, but not p38a, binds to Tollip in the cells
To study the function of Tollip on Exip, we ﬁrst cloned
cDNA encoding full length Tollip and conﬁrmed its DNA
sequence. Then, we examined whether full length Tollip spe-
ciﬁcally binds to full length Exip in mammalian cells. A
co-immunoprecipitation assay was conducted using extracts
prepared from HeLa cells, which had transiently expressed
Flag-hExip or Flag-hp38a, and 3HA-Tollip. We used p38a as
a negative control for showing speciﬁc interaction of Exip to
Tollip. Although the anti-Flag antibody immuno-precipitated
both Exip and p38a (Fig. 2A, third panel), only Exip can co-
precipitate 3HA-Tollip (Fig. 2A, bottom panel). This shows
that Exip, but not p38a, and Tollip speciﬁcally form a complex
in the cells. This also suggests that the speciﬁc C-terminal
domain of Exip is required for the interaction of Exip with
Tollip in mammalian cells. Since Tollip has shown to be in-
volved in the IL-1 signaling pathway, we then conducted ex-
periments to ask if the complex is formed in an IL-1 dependentmanner. A similar co-immunoprecipitation assay described
above was employed and cell extracts were prepared at each
time points after IL-1 stimulation. The complex existed with-
out stimulation and the complex was observed throughout the
experiment (Fig. 2B). The results indicate that the complex
formation is irrespective to IL-1 stimulation.
3.3. Exip associates with IRAK
Tollip has been shown to interact with IRAK in unstimu-
lated cells and dissociate from IRAK upon IL-1 stimulation to
modulate IL-1 signaling pathway [3]. Then, we asked whether
Exip could bind to IRAK. Since a recent study argued that
IRAK and Tollip were not co-puriﬁed in their gel ﬁltration
experiment [19], we tested to see whether Tollip would bind to
IRAK in HEK293T cells in our experimental conditions. The
result obtained from the co-immunoprecipitation assay using
extracts from HEK293T cells transiently expressing 3HA-
Tollip and IRAK clearly showed that both proteins are in the
same complex (Fig. 3A, bottom panel). We then examined the
association of Exip and IRAK in a similar experiment and
found that Exip is in the same complex with IRAK (Fig. 3B).
Although further studies are required to elucidate their mode
of binding, these data support the involvement of Exip in the
IL-1R proximal complex.
3.4. Exip impairs NF-jB activity
Because Exip was observed to associate with Tollip and/or
IRAK, we speculated that Exip may inﬂuence IL-1 signaling
pathway. By using 3 · NF-jB luciferase reporter, we tested the
eﬀect of Exip on IL-1 dependent NF-jB activity (Fig. 4A). Co-
transfection of this reporter into HeLa cells together with
pcDNA3-FlaghExip reduced luciferase activities in a dose
IL-1β(-)
IL-1β(+)
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Fig. 4. Exip impairs NF-jB activity. (A) Exip impairs NF-jB activity
in a dose dependent manner. Increasing amount of Exip or Tollip
expression plasmid ranging from 0 to 0.175 lg (lanes 1–9), or 0 to
0.0875 lg for combination (lanes 10–12) are transfected into HeLa
cells and luciferase activities are measured with (black columns) or
without (white columns) IL-1b stimulation. Relative activities to the
value obtained by pcDNA3FN (lane 1 white column) are shown. The
same experiments are carried out at least three times and a represen-
tative result is shown. (B) Exip impairs NF-jB activity in the presence
of excess amounts of IRAK.
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also observed in HEK293T cells (data not shown). This sug-
gests that Exip, when over-expressed, works as a negative
regulator of NF-jB. It should be also noted that a smaller
amount of Exip expression rather activates NF-jB, suggesting
that Exip has the potential to switch the eﬀect on NF-jB ac-
tivity (Fig. 4A, 1–3). Since Tollip or Exip impaired NF-jB
activity individually, we then tested to see if they could work
together. As shown in Fig. 4A, their eﬀects are only additive
and fail to work synergistically (columns 2, 6, 10 and 4, 8, 12).
The reduction is limited to a certain level, indicating that there
should be a complementary pathway regulating NF-jB activ-
ity (Fig. 4A, 6–9 and 12). The physiological relevance of their
binding should be elucidated. Moreover, Exip reduced not
only IL-1 induced activity but also basal activity of NF-jB
(Fig. 4A, white columns, 2–5) as Tollip did (Fig. 4A, white
columns, 1, 6–9). This impairment of basal NF-jB activity by
increasing amount of Tollip has been shown in the previous
study using LPS as a stimulus [18]. Although Tollip has been
suggested to impair IL-1 dependent NF-jB activity [3], our
observation regarding the eﬀect of Tollip on NF-jB activity issomewhat diﬀerent from the results obtained in the previous
study, in which the cells expressing excess amount of IL-
1RAcP were used [3]. As we discussed earlier, Tollip has been
shown to play diﬀerent roles in the intracellular traﬃcking or
sorting [19,20], Exip as well as Tollip may function in regu-
lating NF-jB activity independent of IL-1with unknown
mechanism(s). Since Exip could bind to IRAK in the cells, we
then tested the eﬀect of Exip on NF-jB activity in the presence
of IRAK. As shown in Fig. 4B, we could not observe any
distinction in the proﬁle of activation governed by Exip
(Fig. 4A, 1–5, Fig. 4B, 1–5). However, the eﬀect of Exip in
combination with Tollip is more obvious in the presence of
IRAK (Fig. 4A, columns 2, 6, 10, Fig. 4B, columns 2, 6, 10).
This suggests that the cooperation of these proteins emerges
with IRAK. As mentioned in the previous study [15], the level
of Exip expression was limited in transient transfections, we
failed to observe the comparative expression of Exip to Tollip
or IRAK in this study as well. This may be one of the reasons
for which we were not able to see a clear cooperative eﬀect on
NF-jB activity with Tollip and/or IRAK. Further studies are
required to clarify the physiological relevance of Exip in in-
ﬂammatory responses with Tollip and/or IRAK. Although the
expression of Exip in the cells is much lower than that of p38a,
we successfully raised the speciﬁc antibody against Exip and
detected its endogenous expression in THP-1 and HL60 (data
not shown). A precise analysis of an endogenous expression of
Exip should be undertaken in the next step to elucidate its
physiological roles in inﬂammatory responses.
Overall, we report here that Exip binds to Tollip and/or
IRAK, and impairs the NF-jB activity both in IL-1 dependent
and independent manners.
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